23 May 2024

Carbapenemaseproducing Enterobacterales in the food chain


Beatriz Guerra/Ernesto Liebana

92th Advisory forum



AS A FOLLOW UP OF THE INFO PRESENTED AT THE 89^{TH} AF MTG...

Carbapenemase-producing E. coli in the food chain in the EU/EFTA



From 2015 -2023

- AT: VIM-1 in broilers 2020, 2022
- BE: VIM-1 in minced pork, 2020
- CZ: 1) NDM-5 pigs; 2) another report in pigs. 1) 2021; 2)
 2023
- DE: 1) VIM-1 in pigs; 2) VIM-1 pig meat; OXA-48, GES-5 pigs 1) 2015, 2017; 2) 2019
- HU: NDM-5 pigs, cattle 2021
- IT: 1) OXA-181 bovines, pigs; OXA-48 pigs, NDM-5 calf; 2) VIM-1 broilers, OXA-181 turkeys; 3) OXA-181 pigs, bovines 1) 2021; 2) 2022; 3) 2023
- NO: NDM-5 cattle 2023
- RO: OXA-162, broilers, 2016
- **ES**: OXA-48 pigs 2021, **2023**

Recent ECDC report:

E. coli carrying *bla*_{NDM-5} is established as a significant concern in humans in EU/EEA.

Spread of *E. coli* isolates carrying *bla*_{NDM-5} is occurring rapidly and on a large geographic scale



BIOHAZ SELF TASK MANDATE: CPES IN FOOD CHAIN

ToR2

ToR3

ToR1	State of the art 2024 To gather information from countries reporting data to EFSA for the AMR monitoring on: (i) planned or on-going studies/investigations spanning from recent surveillance findings (ii) contingency plans and/or control measures implemented/planned to halt their spread (iii) Published reports/papers on occurrence EU/worldwide since previous BIOHAZ Opinion	March 2025
	New data generation, partnership MSs	

To collaborate with the above-mentioned countries and with the EURL-AR with the purpose of generating new data through a specific project (EFSA outsourcing, 2024 to 2026).

Countries interested in participating could express their interest in one or several of the work packages with the following objectives: a) protocols, b) epidemiological studies, c) in depth (WGS) analysis, d) genomics comparison analyses.

State of the art 2027

To **review all new data/evidence** generated by the Member States and the EURL-AR, **issuing one or more scientific opinion(s)** targeting the different topics identified in ToRs 1 and 2.

June 2027

3

03 2024-

03 2026



Received April 2024, in agreement with EC, close collaboration with ECDC, informing EMA, EEA

MANDATE TIMING, OUTPUTS, ORGANIZATION

Time: 3 years, May 2024- June 2027.

Outputs ad hoc:

- ToR1. One initial BIOHAZ scientific opinion presenting the state of the art (including results to a survey to MSs), by March 2025
- ToR2. Monopole Framework Partnership agreement (FPA) with EURL/NRLs-AR Network, external reports, Q3 2024-Q3 2026.
- ToR3. Final BIOHAZ scientific opinion evaluating the results of the project, advice to risk managers, by June 2027
- More scientific opinions in between if needed (e.g. NDM-5)



Biological Hazards



FPA "data generation on CPs in foodproducing animals" Contract: 2.5 years (mid 2024-end 2026), Budget 1.5 mill Co-funding (20%).

Contractor (coordinator + MSs): EURL-AR/NRLs-AR Network labs, Art. 36 https://www.eurl-ar.eu/participants.aspx

ECDC Networks, to collaborate in ToR2d



WG CARBAPENEMASE IN ENTEROBACTERALS (CPEs)



Expertise:

- Antimicrobial resistance (AMR)
- Carbapenemases
- Molecular epidemiology (genes, resistance determinants, plasmids, clones, comparative genomics)
- Isolation, detection and characterization (phenotypic and genotypic) methods
- Food-producing animals and their environment
- Epidemiology

WG Mandate from 2024-2027:

8 experts (panel members, previous CPE/AMR opinions, ECDC Networks), 6 confirmed, 2 still pending. ECDC and EMA staff.

• Luisa Peixe, Chair (BIOHAZ Panel, University of Porto, PT)

Plans 2024: 4 online mtgs, 2 physical ones, from May to December.

Tasks:

- Design and evaluation of survey to the NRLs-AR to gather data/info on going activities.
- Revise deliverables.
- **Contribute to draft scientific opinions** evaluating/review the data generated from the outsourcing, conclusions and recommendations



FRAMEWORK PARTNERSHIP GRANT

To be launched in May/beg. June, Monopole ToR2: Data generation Carbapenemase in Enterobacteriacea to support Self-Task Mandate EURL-AR Network Labs, Art. 36 list. Webinar done on 14 May to inform the Network Framework Partnership The EFSA issues Specific grant agreements (SGAs) Specific grant agreement Agreement (FPA) is signed (EFSA and (SGA) is signed between outlining FPA partner(s) task(s), to contractor) deliverable(s) and timelines EFSA and FPA partner(s) SGI-1, WP0 SGI-2, WP1 SGI-3, WP2 SGI-3, WP3 SGI-3, WP4 ToR2a Project ToR3b ToR2b ToR3b To collect, design coordination To perform One To perform To perform in depth more sensitive Health comparative epidemiological analysis of the detection protocols genomic analyses studies isolates

CONCLUSION AND DISCUSSION

• EFSA has taken action

- Tackled within a **One Health approach**
- The participation of the MSs through the EURL-network laboratories (NRLs) in the planned outsourcing, and data sharing is essential to understand the magnitude of the problem. To be eligible, the Institutions hosting the NRLs shall be included in the EFSA Art. 36 list.
- **Collaboration with the public health laboratories/ECDC Networks** will be essential to address ToR2d, comparative analyses.
- Depending on the findings, **timely advice** will be given to the managers



Thanks for your attention!

Beatriz Guerra, PhD

Lead Expert Molecular Epidemiology. BIOHAW Unit ASSESS Department e-mail: beatriz.guerra@efsa.europa.eu





STAY CONNECTED

SUBSCRIBE TO

3

0

efsa.europa.eu/en/news/newsletters efsa.europa.eu/en/rss Careers.efsa.europa.eu – job alerts

LISTEN TO OUR PODCAST Science on the Menu –Spotify, Apple Podcast and YouTube

FOLLOW US ON TWITTER @efsa_eu (@plants_efsa (

@methods_efsa @animals_efsa FOLLOW US ON LINKEDIN Linkedin.com/company/efsa

in

 \bowtie

FOLLOW US ON INSTAGRAM @one_healthenv_eu CONTACT US efsa.europe.eu/en/contact/askefsa

